US equities |
NVDA $166.19 ▲+0.00% MU $798.44 ▲+0.00% AMD $585.30 ▲+0.00% MSFT $523.00 ▲+0.00% SNDK $937.46 ▲+0.00% TSLA $397.45 ▲+0.00% AVGO $364.36 ▲+0.00% SPCX $139.94 ▲+0.00%
FinancialContent

Imunon, Inc. - Common Stock (NQ:IMNN)

0.6368 UNCHANGED
Delayed Quote Updated: 4:00 PM EST, Nov 12, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about Imunon, Inc. - Common Stock

News headline image
Life Sciences Virtual Investor Forum Presentations Now Available for On-Demand Viewing
From Virtual Investor Conferences
Via GlobeNewswire
News headline image
Life Sciences Virtual Investor Forum Agenda Announced for June 24th & 25th
Company Executives Share Strategic Vision and Engage with Investors Live at VirtualInvestorConferences.com 
From Virtual Investor Conferences
Via GlobeNewswire
News headline image
Life Sciences Investor Forum: Now Available for Online Viewing
Company Executives Share Vision and Answer Questions Live at VirtualInvestorConferences.com 
From Virtual Investor Conferences
Via GlobeNewswire
News headline image
IMUNON Reports Inducement Grants under NASDQ Listing Rule 5646(c)(4)
From Imunon, Inc.
Via GlobeNewswire
News headline image
Life Sciences Investor Forum Agenda Announced for June 11th-12th
Company Executives Share Vision and Answer Questions Live at VirtualInvestorConferences.com 
From Virtual Investor Conferences
Via GlobeNewswire
News headline image
IMUNON Presentation at World Vaccine & Immunotherapy Congress Highlights PLACCINE Preclinical Proof of Concept and Key Competitive Advantages
From Imunon, Inc.
Via GlobeNewswire
News headline image
IMUNON to Participate in the A.G.P./Alliance Global Partners Virtual Biotech Conference on November 30, 2022 – December 1, 2022
From Imunon, Inc.
Via GlobeNewswire
News headline image
IMUNON Announces Strategic Investment in Transomic Technologies
From Imunon, Inc.
Via GlobeNewswire
News headline image
IMUNON Reports Third Quarter 2022 Financial Results and Provides Business Update
From Imunon, Inc.
Via GlobeNewswire
News headline image
IMUNON Enters into Technology Evaluation Agreement with Acuitas Therapeutics to Evaluate IMUNON’s PLACCINE Plasmid DNA with Acuitas’ Lipid Nanoparticle Delivery System
From Imunon, Inc.
Via GlobeNewswire
News headline image
Imunon to Hold Third Quarter 2022 Financial Results and Business Update Conference Call on Monday, November 14, 2022
From Imunon, Inc.
Via GlobeNewswire
News headline image
Imunon Appoints James E. Dentzer to its Board of Directors
From Imunon, Inc.
Via GlobeNewswire
News headline image
Imunon Reports Partial Results from Ongoing Non-human Primate Study
From Imunon, Inc.
Via GlobeNewswire
News headline image
Imunon Reports Inducement Grants under NASDQ Listing Rule 5646(c)(4)
From Imunon, Inc.
Via GlobeNewswire